U.S. markets closed

Orexo AB (publ) (ORX.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
Add to watchlist
44.80-1.65 (-3.55%)
At close: 5:29PM CET

Orexo AB (publ)

Virdings allE 32 A
Uppsala 754 50
Sweden
46 1 87 80 88 00
http://www.orexo.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees138

Key Executives

NameTitlePayExercisedYear Born
Mr. Nikolaj SørensenPres & CEO5.29MN/A1972
Mr. Joseph DeFeoEVP & CFON/AN/A1961
Ms. Cecilia CouplandVP & Head of OperationsN/AN/A1976
Lena WangeHead of Investor Relations & Communications DirectorN/AN/AN/A
Dr. Michael Sumner M.D.Chief Medical OfficerN/AN/A1965
Mr. Johannes DollExec. VP & Chief Commercial OfficerN/AN/A1981
Mr. Robert RönnVP and Head of R&DN/AN/A1976
Mr. Dennis UrbaniakExec. VP of Digital HealthN/AN/A1969
Mr. Robert A. DelucaPres of Orexo US IncN/AN/A1961
Mr. Jesper LindAdvisorN/AN/A1960
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.

Corporate Governance

Orexo AB (publ)’s ISS Governance QualityScore as of December 2, 2020 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.